Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Wednesday, October 22, 2025
Ipsen’s $406 Million Acquisition of ImCheck
Nurix’s $250 million Registered Direct Offering
RAPT’s $250 Million Public Offering
Electra’s $183 Million Series C…MoreMore
Galera’s $105 Million Acquisition of Biossil
Tuesday, October 21, 2025
Viridian’s $251 Million Public Offering
Disc Medicine’s $250 Million Public Offering
Minerva’s $200 Million Private Placement
PleoPharma’s $36 Million Series B
Faeth’s $92 Million Fund Raise
Citius’s $6 Million Registered Direct Offering
XORTX’s $1 Million Registered Direct Offering
Monday, October 20, 2025
Viridian’s $300 Million Royalty Financing
Lexeo’s $154 Million Public Offering
atai’s $150 Million Public Offering
Alto’s $50 Million Private Placement
Friday, October 17, 2025
AB’s $3 Million Private Placement
Thursday, October 16, 2025
Praxis’s $525 Million Public Offering
Town Hall’s $440 Million Fund Raise
Veradermics’ Oversubscribed $150M Series C…More
C4’s $125 Million Public Offering
Adcytherix’s $122 Million Series A
Peptilogics’ $78 Million Series B2
Conexeu’s $5 Million Fund Raise
Wednesday, October 15, 2025
Spyre’s $316 Million Public Offering
Pelage’s $120 Million Series B
Mission’s $13 Million Fund Raise
Akari’s $3 Million Registered Direct Offering
Tuesday, October 14, 2025
BioCryst’s $700 Million Acquisition of Astria
Candel’s $130 Million Debt Financing
EVerZom’s $12 Million Fund Raise
EyePoint’s $11 Million Public Offering
Kardigan’s $254 Million Series B
Monday, October 13, 2025
Excellergy’s $70 Million Series A
ADC’s $60 Million Private Placement
MAIA’s $736 Thousand Private Placement
Friday, October 10, 2025
Bristol Myers’s $1.5 Billion Acquisition of Orbital…More
Apogee’s $345 Million Public Offering
Quoin’s $105 Million Private Placement
Idorsia’s $81 Million Public Offering
Annovis’s $6 Million Registered Direct Offering
Xenetic’s $4 Million Public Offering
Thursday, October 9, 2025
Novo Nordisk’s $5.2 Billion Acquisition of Akero…More
PNP Program Partners
In coordination with an executive placement firm that is independent and unaffiliated with Collabrity, Inc., we may coordinate with executive(s) who are sourced by that firm and also independent and unaffiliated with Collabrity, Inc.: “Collabrity Executive(s)” does not imply an employment or independent contractor relationship with Collabrity, Inc.
Securities offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity Inc. is not a registered broker-dealer, and Finalis Securities LLC and Collabrity Inc. are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck